» Articles » PMID: 15864305

Sensitized RNAi Screen of Human Kinases and Phosphatases Identifies New Regulators of Apoptosis and Chemoresistance

Overview
Journal Nat Cell Biol
Specialty Cell Biology
Date 2005 May 3
PMID 15864305
Citations 212
Authors
Affiliations
Soon will be listed here.
Abstract

Evasion from apoptosis is a hallmark of cancer, and recent success using targeted therapeutics underscores the importance of identifying anti-apoptotic survival pathways. Here we utilize RNA interference (RNAi) to systematically screen the kinase and phosphatase component of the human genome. In addition to known kinases, we identified several new survival kinases. Interestingly, numerous phosphatases and associated regulatory subunits contribute to cell survival, revealing a previously unrecognized general role for phosphatases as negative regulators of apoptosis. We also identified a subset of phosphatases with tumour-suppressor-like activity. Finally, RNAi targeting of specific protein kinases sensitizes resistant cells to chemotherapeutic agents. The development of inhibitors that target these kinases or phosphatases may lead to new anti-cancer strategies.

Citing Articles

Early tolerance and late persistence as alternative drug responses in cancer.

Punzi S, Cittaro D, Gatti G, Crupi G, Botrugno O, Cartalemi A Nat Commun. 2025; 16(1):1291.

PMID: 39900637 PMC: 11790948. DOI: 10.1038/s41467-024-54728-7.


Mitophagy: insights into its signaling molecules, biological functions, and therapeutic potential in breast cancer.

Chen C, Xiang A, Lin X, Guo J, Liu J, Hu S Cell Death Discov. 2024; 10(1):457.

PMID: 39472438 PMC: 11522701. DOI: 10.1038/s41420-024-02226-6.


PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells.

Schaaf Z, Ning S, Leslie A, Sharifi M, Gao R, Maine J Cancer Res Commun. 2024; 4(11):2976-2985.

PMID: 39440945 PMC: 11577557. DOI: 10.1158/2767-9764.CRC-24-0339.


Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.

Kokkorakis N, Zouridakis M, Gaitanou M Pharmaceutics. 2024; 16(4).

PMID: 38675189 PMC: 11053710. DOI: 10.3390/pharmaceutics16040528.


The role of TAOK3 in cancer progression and development as a prognostic marker: A pan-cancer analysis study.

Alasiri G, Alrfaei B, Alaseem A, AlKhamees O, Aldali J, Aljehani A Saudi Pharm J. 2024; 32(3):101942.

PMID: 38318319 PMC: 10840358. DOI: 10.1016/j.jsps.2023.101942.